[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635476":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":83,"collaborators":18,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":18,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":18,"overallStatus":44,"whyStopped":18,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Alfasigma S.p.A.","INDUSTRY",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Filgotinib","EXPERIMENTAL",[12],"Drug: Filgotinib",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","Investigational product (IP) will be provided as commercially developed film-coated tablets or age-appropriate film-coated tablets for use in pediatric subjects aged at least 8 years and needs to be taken orally once daily (q.d.) at approximately the same time every morning (with or without food)",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Catherine Vincent","CONTACT","00800 7878 1345","medicalinfo@alfasigma.com",[26,42,57,69],{"facility":27,"status":28,"city":29,"state":18,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Bicetre Hospital","NOT_YET_RECRUITING","Le Kremlin-Bicêtre","94270","France","FR",{"type":34,"coordinates":35},"Point",[36,37],2.36073,48.81471,{"lat":37,"lon":36},[40],{"name":41,"role":22,"phone":18,"phoneExt":18,"email":18},"Isabelle Kone-Paut, Dr.",{"facility":43,"status":44,"city":45,"state":18,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Hamburger Zentrum für Kinder- und Jugendrheumatologie","RECRUITING","Hamburg","22081","Germany","DE",{"type":34,"coordinates":50},[51,52],9.99302,53.55073,{"lat":52,"lon":51},[55],{"name":56,"role":22,"phone":18,"phoneExt":18,"email":18},"Ivan Foeldvari, Dr.",{"facility":58,"status":28,"city":59,"state":18,"zip":60,"country":47,"countryCode":48,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Asklepios Klinik Sankt Augustin GmbH","Sankt Augustin","53757",{"type":34,"coordinates":62},[63,64],7.197,50.77538,{"lat":64,"lon":63},[67],{"name":68,"role":22,"phone":18,"phoneExt":18,"email":18},"Gerd Horneff, Dr",{"facility":70,"status":28,"city":71,"state":18,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Great Ormond Street Hospital for Children","London","WC1N 3JH","United Kingdom","UK",{"type":34,"coordinates":76},[77,78],-0.12574,51.50853,{"lat":78,"lon":77},[81],{"name":82,"role":22,"phone":18,"phoneExt":18,"email":18},"Sandrine Lacassagne, Dr.",{"type":84,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100635476","phase-3-ole-study-with-filgotinib-in-jia-100635476",false,"NCT07553182","OLE Study With Filgotinib in JIA","Open-label Extension (OLE), Multiple Dose Study to Evaluate Safety, Tolerability, and Efficacy of Filgotinib in Children and Adolescents From 8 Years to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis (JIA)","OLE JIA","Inclusion Criteria:\n\n* Subject must have completed treatment with filgotinib in at least one parent study and achieved a clinical benefit at the end of the parent protocols\n* Subject and\u002For parent\u002Flegal guardian must be able and willing to comply with the clinical study protocol requirements and must sign and date the informed consent form and assent (if required per local regulation) as approved by the Independent Ethics Committee\u002F Institutional Review Board, prior to any protocol evaluations\n* Female or male subject 8 to \\\u003C18 years of age, on the date of signing the informed consent and assent (per local regulation) form\n* Female subject of childbearing potential who is sexually active and at risk for pregnancy must agree to use contraception\u002Fpreventive exposure measures as described in the clinical study protocol.\n\nExclusion Criteria:\n\n* Development of any condition during the parent study that would preclude safe continuation\n* Pregnancy\n* Active infection that is clinically significant, as per Investigator's judgement\n* Subject with known hypersensitivity to the components of potential study therapy\n* Subjects with any condition or circumstances (including abnormalities in laboratory parameters) that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements","ALL","8 Years","18 Years",{"count":97,"type":98},80,"ESTIMATED","INTERVENTIONAL",[101],"PHASE3","This OLE study is designed to evaluate long-term safety, tolerability, and efficacy of filgotinib in patients with polyarticular or systemic juvenile idiopathic arthritis (pJIA-sJIA) who have completed the treatment period\u002Fprolonged treatment period of the parent studies and demonstrated clinical benefit defined as control of disease activity through improvement in signs and symptoms as per Investigator judgement.",[104],"Juvenile Idiopathic Arthritis (JIA)","2026-04-21",{"date":107,"type":108},"2026-04-27","ACTUAL",{"date":110,"type":108},"2026-04-20",{"date":112,"type":98},"2027-12",{"name":5,"class":6},4]